Review of drugs accepted by CDE in April 2014 (2)
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
In April 2014, CDE accepted 63 clinical applications for new drugs of 2-5 categories of chemicals, including 9 anti-tumor drugs, 7 respiratory drugs, 6 digestive system drugs, 6 blood and hematopoietic system drugs In April, among the 2-5 kinds of new chemical drugs clinical applications accepted by CDE, Zhengda Tianqing Pharmaceutical Group Co., Ltd has 6 varieties, which is the enterprise with the most clinical applications of such new drugs; Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shijiazhuang Zhiheng Pharmaceutical Technology Co., Ltd., huarunsaike Pharmaceutical Co., Ltd., Wuhan pharmaceutical Valley Bioengineering Co., Ltd., Jiangsu Haosen Pharmaceutical Co., Ltd Ltd., Qilu Pharmaceutical Co., Ltd and Lianyungang Runzhong Pharmaceutical Co., Ltd have 4 varieties of application respectively In April, among the clinical applications of 2-5 kinds of chemical drugs accepted by CDE, there are 6 enterprises applying for the new drugs of midana, and 4 enterprises applying for the new drugs of tadalafil, prasugrel, azilsartan, dimethorphine and kabataxai, respectively Table 2-5 clinical applications (preparations) of new chemical drugs accepted by CDE in April 2014
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.